Advertisement
ALC vs DHR
Which Stock Would AI Choose? Alcon Inc. (ALC) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- ALC is a leading eye-care company gaining traction from new product launches, though tariff costs and intense competition are pressuring near-term margins.
- DHR is a diversified life-sciences and diagnostics conglomerate whose biotechnology segment is recovering, supported by a large pending acquisition and an AI collaboration.
- The two companies operate in different healthcare niches, making this a contrast between a focused medical-device franchise and a broad scientific-tools platform.
- Analyst sentiment is constructive on both, with consensus Buy-type ratings, though ALC carries a larger implied upside target than DHR.
- Relative momentum differs: DHR has benefited from bioprocessing demand, while ALC is contending with slower procedure-volume growth.
Introduction
Investors comparing ALC and DHR are weighing two distinct healthcare growth stories. ALC (Alcon Inc.) is a pure-play eye-care business spanning surgical equipment, intraocular lenses, contact lenses, and ocular-health products. DHR (Danaher Corporation) is a diversified life-sciences, biotechnology, and diagnostics leader. This stock comparison is relevant for traders assessing relative performance and market positioning across medical technology, as well as for longer-term investors evaluating two companies with different risk profiles, growth drivers, and sector exposures.
ALC Overview and Recent Performance
Alcon is a global leader in eye care, generating revenue across two segments: Surgical (implantables, consumables, and equipment such as the UNITY platform) and Vision Care (contact lenses and ocular-health products). Recent weeks have highlighted a strong product-launch cadence, including continued adoption of PanOptix Pro intraocular lenses, the TRYPTYR dry-eye treatment, and the Valeda platform for dry age-related macular degeneration.
Recent quarterly results showed solid top-line growth, with sales rising at a high-single-digit rate on a constant-currency basis (constant currency, or "cc," removes foreign-exchange effects), driven by equipment and ocular-health momentum. However, reported operating margin declined as the company absorbed efficiency-initiative costs, intangible-asset impairments, incremental tariffs, and higher spending behind launches. Management has assumed U.S. import tariff rates near 10% to 12.5% persisting, and global procedure volumes have grown only modestly. Analysts generally maintain a Buy consensus, and Alcon has been active in returning capital through dividends and share repurchases.
DHR Overview and Recent Performance
Danaher operates through three segments: Biotechnology, Life Sciences, and Diagnostics. Its Danaher Business System, a continuous-improvement operating model, underpins acquisitions and margin expansion. In recent market activity, the company has been propelled by renewed bioprocessing demand, with biotechnology core revenue growing in the mid-to-high single digits and equipment orders rising sharply as pharmaceutical customers invest in drug manufacturing.
Danaher reported first-quarter 2026 revenue of approximately $5.95 billion, up 3.5% year over year, with core revenue up 0.5% on a non-GAAP (generally accepted accounting principles) basis that excludes currency and other items. Diagnostics remained a laggard, with core sales declining, partly reflecting softer respiratory testing. Sentiment has also been shaped by the anticipated acquisition of Masimo for $180 per share in cash and, more recently, a collaboration with NVIDIA focused on autonomous science. The company guided full-year core revenue growth of roughly 3% to 6%.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance statistics, and set of tickers, giving users a range of approaches across different risk profiles and holding periods. Because market conditions shift, the robots highlighted as trending reflect the strategies currently demonstrating the strongest alignment with the prevailing environment. Investors can explore these tools to see how algorithmic systems evaluate relative performance and market positioning.
Head-to-Head Comparison
The most fundamental contrast is business-model concentration versus diversification. ALC is entirely exposed to eye care, which gives it focused expertise and strong franchise positions but leaves it sensitive to procedure volumes, tariffs, and competitive pricing. DHR spans biotechnology, life sciences, and diagnostics, spreading risk across end markets but also creating exposure to cyclical bioprocessing spending and acquisition-integration risk.
Growth drivers differ as well. ALC is leaning on product innovation and market-share gains across lenses and equipment, while DHR is riding a bioprocessing recovery, monoclonal-antibody demand (antibodies used in biopharmaceutical therapies), and strategic acquisitions. In terms of market sentiment, DHR has benefited from clearer near-term catalysts, including its Masimo transaction and AI partnership, whereas ALC faces tariff and competitive headwinds that have weighed on its recent valuation. On scale, Danaher is materially larger by market capitalization and revenue, while Alcon trades at a comparatively higher implied analyst upside relative to its current price.
Tickeron AI Verdict
Based on observable trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely tilt toward DHR in the current environment. Danaher presents a more diversified revenue base, a recovering biotechnology segment with strengthening order momentum, and concrete near-term catalysts from its pending acquisition and AI collaboration. Alcon's fundamentals remain solid, but its trend signal is currently tempered by tariff-related margin pressure and softer procedure-volume growth. The distinction is probabilistic rather than definitive: ALC could reassert momentum if its product launches accelerate, while DHR remains sensitive to the pace of the bioprocessing recovery and execution on its acquisition strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and DHR is a Hold.
ALC in upward trend: price rose above 50-day moving average on October 22, 2026
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 23 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALC as a result. In 61 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 28 of 53 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ALC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.509) is normal, around the industry mean (4.961). P/E Ratio (51.083) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.015) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
DHR in downward trend: price may drop because broke its higher Bollinger Band on October 15, 2026
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 27 of the 42 cases the stock fell afterwards. This puts the odds of success at 64%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 13 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 57 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for DHR just turned positive on October 14, 2026. Looking at past instances where DHR's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 174 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 111 of 199 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.127) is normal, around the industry mean (66.046). P/E Ratio (41.465) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
ALC | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 15 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 88 | 77 | |
PRICE GROWTH RATING 1..100 | 56 | 14 | |
P/E GROWTH RATING 1..100 | 10 | 53 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (18) in the Medical Specialties industry is somewhat better than the same rating for ALC (69) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew somewhat faster than ALC’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as ALC (88) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew similarly to ALC’s over the last 12 months.
DHR's Price Growth Rating (14) in the Medical Specialties industry is somewhat better than the same rating for ALC (56) in the Hospital Or Nursing Management industry. This means that DHR’s stock grew somewhat faster than ALC’s over the last 12 months.
ALC's P/E Growth Rating (10) in the Hospital Or Nursing Management industry is somewhat better than the same rating for DHR (53) in the Medical Specialties industry. This means that ALC’s stock grew somewhat faster than DHR’s over the last 12 months.
| ALC | DHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 45% |
| Stochastic ODDS (%) | 1 day ago 49% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 53% | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 58% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 57% |
| Advances ODDS (%) | 8 days ago 57% | 8 days ago 55% |
| Declines ODDS (%) | 4 days ago 56% | 3 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 66% | 1 day ago 64% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green while DHR’s FA Score has 2 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- ALC’s TA Score: 4 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +6.08% price change this week, while DHR (@Medical Specialties) price change was +4.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
ALC is expected to report earnings on Nov 10, 2026.
DHR is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -1.76% | ||
| TMO - DHR | 73% Closely correlated | -2.52% | ||
| RGEN - DHR | 68% Closely correlated | -0.72% | ||
| BIO - DHR | 64% Loosely correlated | +0.83% | ||
| A - DHR | 60% Loosely correlated | -2.17% | ||
| BRKR - DHR | 58% Loosely correlated | -3.04% | ||
More | ||||